Effect of Infliximab Treatment on QT Intervals in Patients With Ankylosing Spondylitis

Basit Öğe Kaydı
dc.contributor.authorSenel, Soner
dc.contributor.authorCobankara, Veli
dc.contributor.authorTaskoylu, Ozgur
dc.contributor.authorGuclu, Aydin
dc.contributor.authorEvrengul, Harun
dc.contributor.authorKaya, Mehmet Gungor
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T10:04:50Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T10:04:50Z
dc.date.issued2011
dc.department[Senel, Soner] Cumhuriyet Univ, Sch Med, Dept Internal Med, Div Rheumatol, Sivas, Turkey -- [Cobankara, Veli] Pamukkale Univ, Sch Med, Dept Internal Med, Div Rheumatol, Denizli, Turkey -- [Taskoylu, Ozgur -- Evrengul, Harun] Pamukkale Univ, Sch Med, Dept Cardiol, Denizli, Turkey -- [Kaya, Mehmet Gungor] Erciyes Univ, Sch Med, Dept Cardiol, Kayseri, Turkeyen_US
dc.description.abstractBackground: Cardiovascular complications are one of the most common and the most serious extraskeletal manifestations of ankylosing spondylitis (AS). Infliximab, a monoclonal antibody against tumor necrosis factor, is widely used in the treatment of AS. QT dispersion (QTd), which relates to left ventricular function and is used as an index of cardiac dysrhythmia, may be useful as a prognostic guide. Early detection of possible cardiac involvement may not be clinically evident, whereas it may be detected by electrocardiography. Objectives: The aim of this prospective study was to assess the effect of infliximab treatment on QT intervals in patients with AS. Methods: Twenty-one patients (17 females and 4 males) with AS who were in the active phase of disease (Bath Ankylosing Spondylitis Disease Activity Index score >4) were enrolled in the study. Infliximab was administered intravenously at a dosage of 5 mg/kg at weeks 0, 2, and 6 and every 6 weeks thereafter. QT intervals were recorded before and after 6 months of treatment. Results: QT corrected (QTc) for heart rate was significantly reduced in the patients with AS after 6 months of infliximab therapy (406 +/- 5.5 vs 388 +/- 6.6 milliseconds; P = 0.029). There was no difference in the QTc dispersion (34.3 +/- 11.1 vs 34.1 +/- 8.6; P = 0.171). Body mass index and lipid profile were slightly increased after the treatment, but the difference was statistically insignificant. Conclusion: Inflammation can affect the ventricles with an unknown mechanism, and QTc may be slightly prolonged as a result in the active phase of AS. In our study, QTc was shortened under infliximab therapy by suppressing inflammation. Therefore, this effect may protect patients with AS from fatal arrhythmias and sudden cardiac death.en_US
dc.identifier.endpage1275en_US
dc.identifier.issn1081-5589
dc.identifier.issue8en_US
dc.identifier.pmid21955979en_US
dc.identifier.scopus2-s2.0-84856720070en_US
dc.identifier.scopusqualityQ2
dc.identifier.startpage1273en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12418/9405
dc.identifier.volume59en_US
dc.identifier.wosWOS:000297247000021en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLIPPINCOTT WILLIAMS & WILKINSen_US
dc.relation.ispartofJOURNAL OF INVESTIGATIVE MEDICINEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectankylosing spondylitisen_US
dc.subjectcardiovascular involvementen_US
dc.subjectinfliximaben_US
dc.subjectQT dispersionen_US
dc.titleEffect of Infliximab Treatment on QT Intervals in Patients With Ankylosing Spondylitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu